Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorRADIN, Massimo
dc.contributor.authorUGOLINI-LOPES, Michelle Remiao
dc.contributor.authorSCIASCIA, Savino
dc.contributor.authorANDRADE, Danieli
dc.date.accessioned2018-09-13T15:27:44Z
dc.date.available2018-09-13T15:27:44Z
dc.date.issued2018
dc.description.abstractObjectives: Extra-criteria manifestations of antiphospholipid syndrome (APS) might impact on prognosis and morbidity of the disease. In this study, we aimed to evaluate a population of patients with primary APS (PAPS) whether the extra-criteria manifestations were more frequently found in subjects with higher adjusted Global APS Score (aGAPSS) values when compared to patients with thrombotic and/or obstetric APS (""criteria"" manifestations) only. Methods: Clinical records were analyzed to retrieve extra-criteria manifestation of APS, cardiovascular risk factors and antiphospholipid antibodies profile. The aGAPSS was calculated by adding the points, as follows: 3 for hyperlipidaemia, 1 for arterial hypertension, 5 for anticardiolipin antibodies IgG/IgM, 4 for anti-beta 2 glycoprotein I IgG/IgM, and 4 for lupus anticoagulant. Results: This retrospective multicenter study included 89 consecutive PAPS [mean age 43.1 (S.D. +/- 12.9), female 67%, 52% arterial and 65% venous]. Twenty-seven patients (30.3%) had a history of livedo, 19 (21.3%) had a history of confirmed thrombocytopenia, 3 (3.4%) had biopsy-proven antiphospholipid antibodies (aPL)-related nephropathy and 3 (3.4%) had a history of valvulopathy. Patients with extra criteria manifestations presented a mean aGAPSS significantly higher [mean 10.30 (S.D. +/- 3.57, range: 4-17) vs mean 8.16 (S.D. +/- 3.52;range: 4-16, p = 0.005). When comparing patients with and without extra-criteria manifestations, the first group had significantly higher incidence of anti-beta 2GPI antibodies positivity (59% and 33%, respectively, p = 0.015), double aPL positivities (53% and 31%, respectively, p = 0.034), cerebrovascular events history (52% and 24%, respectively, p = 0.007) and arterial hypertension (52% and 24%, respectively, p = 0.007). Conclusions: Our results suggest that patients with higher aGAPSS, might be at higher risk for developing extra-criteria manifestations of APS and should therefore undergo a thorough laboratory and instrumental evaluation.
dc.description.indexMEDLINE
dc.identifier.citationSEMINARS IN ARTHRITIS AND RHEUMATISM, v.48, n.1, p.117-120, 2018
dc.identifier.doi10.1016/j.semarthrit.2017.12.006
dc.identifier.eissn1532-866X
dc.identifier.issn0049-0172
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/28380
dc.language.isoeng
dc.publisherW B SAUNDERS CO-ELSEVIER INC
dc.relation.ispartofSeminars in Arthritis and Rheumatism
dc.rightsrestrictedAccess
dc.rights.holderCopyright W B SAUNDERS CO-ELSEVIER INC
dc.subjectAntiphosphospholipid syndrome
dc.subjectAPS
dc.subjectLivedo
dc.subjectThrombocytopenia
dc.subjectGAPSS
dc.subjectaGAPSS
dc.subjectRisk score
dc.subjectThrombosis
dc.subject.othersyndrome score
dc.subject.othersyndrome aps
dc.subject.othercohort
dc.subject.otherupdate
dc.subject.othervalidation
dc.subject.otherthrombosis
dc.subject.othergapss
dc.subject.wosRheumatology
dc.titleExtra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management
dc.typearticle
dc.type.categoryreview
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryItália
hcfmusp.affiliation.countryisoit
hcfmusp.author.externalRADIN, Massimo:Univ Turin, Dept Clin & Biol Sci, Ctr Res Immunopathol & Rare Dis, Coordinating Ctr Piemonte & Valle Aosta Network R, Turin, Italy; Univ Turin, SCDU Nephrol & Dialysis, Turin, Italy; S Giovanni Bosco Hosp, Turin, Italy
hcfmusp.author.externalSCIASCIA, Savino:Univ Turin, Dept Clin & Biol Sci, Ctr Res Immunopathol & Rare Dis, Coordinating Ctr Piemonte & Valle Aosta Network R, Turin, Italy; Univ Turin, SCDU Nephrol & Dialysis, Turin, Italy; S Giovanni Bosco Hosp, Turin, Italy
hcfmusp.citation.scopus37
hcfmusp.contributor.author-fmusphcMICHELLE REMIAO UGOLINI LOPES
hcfmusp.contributor.author-fmusphcDANIELI CASTRO OLIVEIRA DE ANDRADE
hcfmusp.description.beginpage117
hcfmusp.description.endpage120
hcfmusp.description.issue1
hcfmusp.description.volume48
hcfmusp.origemWOS
hcfmusp.origem.pubmed29395258
hcfmusp.origem.scopus2-s2.0-85041002491
hcfmusp.origem.wosWOS:000441703600016
hcfmusp.publisher.cityPHILADELPHIA
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceAbreu MM, 2015, AUTOIMMUN REV, V14, P401, DOI 10.1016/j.autrev.2015.01.002
hcfmusp.relation.referenceAmengual O, 1996, BRIT J RHEUMATOL, V35, P1239
hcfmusp.relation.referenceAmigo MC, 2014, LUPUS, V23, P1259, DOI 10.1177/0961203314534307
hcfmusp.relation.referenceAndreoli L, 2013, ARTHRIT CARE RES, V65, P1869, DOI 10.1002/acr.22066
hcfmusp.relation.referenceBRANDT JT, 1995, THROMB HAEMOSTASIS, V74, P1185
hcfmusp.relation.referenceCervera R, 2002, ARTHRITIS RHEUM, V46, P1019, DOI 10.1002/art.10187
hcfmusp.relation.referenceChighizola CB, 2015, LUPUS, V24, P980, DOI 10.1177/0961203315572714
hcfmusp.relation.referenceD'Agostino RB, 2008, CIRCULATION, V117, P743, DOI 10.1161/CIRCULATIONAHA.107.699579
hcfmusp.relation.referenceErkan D, 2012, LUPUS, V21, P695, DOI 10.1177/0961203312437810
hcfmusp.relation.referenceMosteirin NF, 2017, LUPUS, V26, P1328, DOI 10.1177/0961203317703493
hcfmusp.relation.referenceHarris EN, 1986, CLIN EXP IMMUNOL, V68, P22
hcfmusp.relation.referenceMassimo Radin, 2017, EUR J NEUROL, DOI [10.1111/ene.13499, DOI 10.1111/ENE.13499]
hcfmusp.relation.referenceMiyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x
hcfmusp.relation.referenceNochy D, 2003, ANN MED INTERNE, V154, P51
hcfmusp.relation.referenceOku K, 2015, LUPUS, V24, P774, DOI 10.1177/0961203314561284
hcfmusp.relation.referencePengo V, 2009, J THROMB HAEMOST, V7, P1737, DOI 10.1111/j.1538-7836.2009.03555.x
hcfmusp.relation.referenceRadin M, 2017, INT J CARDIOL, V240, P72, DOI 10.1016/j.ijcard.2017.02.155
hcfmusp.relation.referenceRosa RF, 2015, CURR RHEUMATOL REP, V17, DOI 10.1007/s11926-015-0502-7
hcfmusp.relation.referenceSciascia S, 2014, LUPUS, V23, P1286, DOI 10.1177/0961203314541317
hcfmusp.relation.referenceSciascia S, 2017, NAT REV RHEUMATOL, V13, DOI 10.1038/nrrheum.2017.124
hcfmusp.relation.referenceSciascia Savino, 2016, Clin Mol Allergy, V14, P6, DOI 10.1186/s12948-016-0043-2
hcfmusp.relation.referenceSciascia S, 2015, RHEUMATOLOGY, V54, P134, DOI 10.1093/rheumatology/keu307
hcfmusp.relation.referenceSciascia S, 2015, ANN RHEUM DIS, V74, P2028, DOI 10.1136/annrheumdis-2014-205663
hcfmusp.relation.referenceSciascia S, 2014, ARTHRIT CARE RES, V66, P1915, DOI 10.1002/acr.22388
hcfmusp.relation.referenceSciascia S, 2013, RHEUMATOLOGY, V52, P1397, DOI 10.1093/rheumatology/kes388
hcfmusp.relation.referenceSciascia Savino, 2017, RHEUMATOLOGY OXFORD
hcfmusp.relation.referenceZuily S, 2015, RHEUMATOLOGY, V54, P2071, DOI 10.1093/rheumatology/kev238
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublicationae8b2495-d8b0-455e-9cc3-acc8f6763f8f
relation.isAuthorOfPublication89219896-6125-4035-9e68-08da2f4a54c1
relation.isAuthorOfPublication.latestForDiscoveryae8b2495-d8b0-455e-9cc3-acc8f6763f8f
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_RADIN_Extracriteria_manifestations_of_antiphospholipid_syndrome_Risk_assessment_and_2018.PDF
Tamanho:
330.98 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/17
Artigos e Materiais de Revistas Científicas - ODS/03